Molecular structure of PD 166285, CAS Number: 212391-63-4
PD 166285 (CAS 212391-63-4)
See product citations (2)
Alternate Names:
Heparin-Cantithrombin II
Application:
PD 166285 is an inhibitor of RTK, c-Src, FGFR1, Wee 1, and PDGFRβ
CAS Number:
212391-63-4
Purity:
≥98%
Molecular Weight:
585.35
Molecular Formula:
C26H27Cl2N5O2•2HCl
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
PD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1), and PDGFRbeta (platelet-derived growth factor receptor beta) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). PD 166285 also inhibits the checkpoint kinases Wee1 and MYT1 (Myt1), abolishes Cdc2 phosphorylation in numerous tumor cell lines, and abrogates the G2 checkpoint. PD 166285 is an RTK inhibitor with broad-spectrum properties and displays anti-angiogenic activity and anti-tumor efficacy when used with PDT (photodynamic therapy). PD 166285 is an inhibitor of EGFR.
PD 166285 (CAS 212391-63-4) References
- A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. | Adams, J., et al. 2002. Curr Opin Chem Biol. 6: 486-92. PMID: 12133725
- American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. | Lavelle, F. 1999. Expert Opin Investig Drugs. 8: 903-9. PMID: 15992139
- Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. | Leijen, S., et al. 2010. Curr Clin Pharmacol. 5: 186-91. PMID: 20406171
- Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. | Krajewska, M., et al. 2013. Oncogene. 32: 3001-8. PMID: 22797065
- A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor. | Lotz-Jenne, C., et al. 2016. Oncotarget. 7: 25983-6002. PMID: 27036020
- MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. | Bridges, KA., et al. 2016. Oncotarget. 7: 71660-71672. PMID: 27690219
- Calibrated mitotic oscillator drives motile ciliogenesis. | Al Jord, A., et al. 2017. Science. 358: 803-806. PMID: 28982797
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. | Boussios, S., et al. 2019. Diagnostics (Basel). 9: PMID: 31374917
- The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. | Pichard, A., et al. 2020. Leukemia. 34: 1315-1328. PMID: 31836849
- Cyclin A triggers Mitosis either via the Greatwall kinase pathway or Cyclin B. | Hégarat, N., et al. 2020. EMBO J. 39: e104419. PMID: 32350921
- An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry. | Hruba, L., et al. 2022. Biomed Pharmacother. 146: 112549. PMID: 34923338
- Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein. | Yamamoto, M., et al. 2022. mBio. 13: e0051922. PMID: 35708281
- In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. | Panek, RL., et al. 1997. J Pharmacol Exp Ther. 283: 1433-44. PMID: 9400019
Inhibitor of:
c-Src, c-Yes, EGFR, Flg, MYT1, PDGFR-beta, Tyrosine Kinase, and Wee 1.Activator of:
C7, and MAP-4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PD 166285, 5 mg | sc-208153 | 5 mg | $146.00 |